Untitled

Betbeder, Didier; Spérandio, S; Latapie, Jean-Philippe; Nadai, J de; Etienne, A.; Zajac, J.-M.; Francés, Bernard

doi:10.1023/a:1007594602449

Cited by 51 publications

(10 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite morphine was actually not nanoencapsulated, indeed nanoparticles improved its nose-to-brain transport, while blood levels were not significantly affected. This was likely due to the interaction of the positive nanoparticles with the nasal mucus layer, which may have increased the formulation residence time and absorption from the olfactory region that is particulary developed in mice [ 87 ].…”

Section: Mucoadhesive Nanoparticlesmentioning

confidence: 99%

Surface-Modified Nanocarriers for Nose-to-Brain Delivery: From Bioadhesion to Targeting

et al. 2018

View full text Add to dashboard Cite

In the field of nasal drug delivery, nose-to-brain delivery is among the most fascinating applications, directly targeting the central nervous system, bypassing the blood brain barrier. Its benefits include dose lowering and direct brain distribution of potent drugs, ultimately reducing systemic side effects. Recently, nasal administration of insulin showed promising results in clinical trials for the treatment of Alzheimer’s disease. Nanomedicines could further contribute to making nose-to-brain delivery a reality. While not disregarding the need for devices enabling a formulation deposition in the nose’s upper part, surface modification of nanomedicines appears the key strategy to optimize drug delivery from the nasal cavity to the brain. In this review, nanomedicine delivery based on particle engineering exploiting surface electrostatic charges, mucoadhesive polymers, or chemical moieties targeting the nasal epithelium will be discussed and critically evaluated in relation to nose-to-brain delivery.

show abstract

Section: Mucoadhesive Nanoparticlesmentioning

confidence: 99%

Surface-Modified Nanocarriers for Nose-to-Brain Delivery: From Bioadhesion to Targeting

et al. 2018

View full text Add to dashboard Cite

show abstract

“…For instance, maltodextrin has been used [91]. When these 60 nm nanoparticles (Biovector) were applied together with morphine, the duration of the antinociceptive activity was increased.…”

Section: Improvement Of the Nose-to-brain Pathway Through Formulatmentioning

confidence: 99%

Formulations for Intranasal Delivery of Pharmacological Agents to Combat Brain Disease: A New Opportunity to Tackle GBM?

Woensel

Wauthoz

Rosière

et al. 2013

Cancers

130

View full text Add to dashboard Cite

Despite recent advances in tumor imaging and chemoradiotherapy, the median overall survival of patients diagnosed with glioblastoma multiforme does not exceed 15 months. Infiltration of glioma cells into the brain parenchyma, and the blood-brain barrier are important hurdles to further increase the efficacy of classic therapeutic tools. Local administration methods of therapeutic agents, such as convection enhanced delivery and intracerebral injections, are often associated with adverse events. The intranasal pathway has been proposed as a non-invasive alternative route to deliver therapeutics to the brain. This route will bypass the blood-brain barrier and limit systemic side effects. Upon presentation at the nasal cavity, pharmacological agents reach the brain via the olfactory and trigeminal nerves. Recently, formulations have been developed to further enhance this nose-to-brain transport, mainly with the use of nanoparticles. In this review, the focus will be on formulations of pharmacological agents, which increase the nasal permeation of hydrophilic agents to the brain, improve delivery at a constant and slow release rate, protect therapeutics from degradation along the pathway, increase mucoadhesion, and facilitate overall nasal transport. A mounting body of evidence is accumulating that the underexplored intranasal delivery route might represent a major breakthrough to combat glioblastoma.

show abstract

“…Nanoparticulate drug delivery systems have been reported to improve the bioavailability of drugs upon intranasal administration as compared to drug solutions (Fernández-Urrusuno et al, 1999; Betbeder et al, 2000; Janes et al, 2001; Vila et al, 2002; Nagamoto et al, 2004). These formulations were shown to increase the residence time in the nasal cavity and also protect the drugs from the enzymatic degradation (Vila et al, 2002).…”

Section: Introductionmentioning

confidence: 99%

Formulation and evaluation of carnosic acid nanoparticulate system for upregulation of neurotrophins in the brain upon intranasal administration

Vaka

Shivakumar

Repka

et al. 2012

Journal of Drug Targeting

View full text Add to dashboard Cite

To develop formulations of carnosic acid nanoparticles and to assess their in vivo efficacy to enhance the expression of neurotrophins in rat model. Carnosic acid loaded chitosan nanoparticles were prepared by ionotropic gelation technique using central composite design. Response surface methodology was used to assess the effect of three factors namely chitosan concentration (0.1–1% w/v), tri-poly phosphate concentration (0.1–1% w/v) and sonication time (2–10 min) on the response variables such as particle size, zeta potential, drug encapsulation efficiency and drug release. The neurotrophins level in the rat brain upon intranasal administration of optimized batch of carnosic acid nanoparticles was determined. The experimental values for the formulation were in good agreement with those predicted by the mathematical models. A single intranasal administration of the optimized formulation of carnosic acid nanoparticles was sufficient to result in comparable levels of endogenous neurotrophins level in the brain that was almost on par with four, once a day intranasal administration of solution in rats. The results clearly demonstrated the fact that nanoparticulate drug delivery system for intranasal administration of carnosic acid would require less number of administrations to elicit the required pharmacological activity owing to its ability to localize on the olfactory mucosal region and provide controlled delivery of carnosic acid for prolonged time periods.

show abstract

Untitled

Abstract: These results show the presence of nanoparticles only at a very specific dose increases the antinociceptive activity of nasal morphine in mice. The occurrence of a direct transport of morphine from the nasal mucosa to the brain is discussed.

Cited by 51 publications

References 23 publications

Surface-Modified Nanocarriers for Nose-to-Brain Delivery: From Bioadhesion to Targeting

Surface-Modified Nanocarriers for Nose-to-Brain Delivery: From Bioadhesion to Targeting

Formulations for Intranasal Delivery of Pharmacological Agents to Combat Brain Disease: A New Opportunity to Tackle GBM?

Formulation and evaluation of carnosic acid nanoparticulate system for upregulation of neurotrophins in the brain upon intranasal administration

Contact Info

Product

Resources

About